Announcements Trials

Browse Landscape

Phase

Phase NA 11 Phase 4 3 Phase 2 2 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 4 Uterine Cervical Neoplasms 2 Uterine Cervical Dysplasia 2 Sarcoma 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Osteoporosis 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Infertility, Female 1 Elective Surgery for Any Digestive Cancer 1 Crohn Disease 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Ductal Infiltrating Metastatic 1 Barrett Esophagus 1 Airway Obstruction 1

Interventions

Dacarbazine 25 Nivolumab 24 pembrolizumab 19 Ipilimumab 18 Interferon-alpha 10 trametinib 8 Vemurafenib 8 dabrafenib 7 aldesleukin 7 Temozolomide 7 Introns 7 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 Chemotherapy, Adjuvant 5 talimogene laherparepvec 4 cemiplimab 4 binimetinib 4 Radiotherapy 4 Paclitaxel 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 sargramostim 3 encorafenib 3 cobimetinib 3 Vinblastine 3 Surgical Procedures, Operative 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Opdualag 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × Blood Specimen Collection × Clear all

NCT02278887 2025-03-10

TIL

The Netherlands Cancer Institute

Phase 3 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡